TipRanks (Wed, 22-Jul 10:30 AM ET)
Globe Newswire (Tue, 21-Jul 8:30 AM ET)
Globe Newswire (Wed, 15-Jul 8:30 AM ET)
PRNewswire (Thu, 25-Jun 11:35 AM ET)
Globe Newswire (Tue, 23-Jun 8:30 AM ET)
Market Chameleon (Fri, 12-Jun 6:46 AM ET)
Globe Newswire (Thu, 11-Jun 8:30 AM ET)
Globe Newswire (Wed, 3-Jun 8:30 AM ET)
Globe Newswire (Mon, 1-Jun 9:00 AM ET)
Alpha Tau’s Q1 2026 Results: Clinical Milestones Signal Momentum in Oncology Innovation
Market Chameleon (Tue, 19-May 7:08 AM ET)
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
Alpha Tau Medical Ltd. - trades on the NASDAQ stock market under the symbol DRTS.
As of July 27, 2026, DRTS stock price was flat at $12.50 with 22,395 million shares trading.
DRTS has a beta of 1.90, meaning it tends to be more sensitive to market movements. DRTS has a correlation of 0.12 to the broad based SPY ETF.
DRTS has a market cap of $1.13 billion. This is considered a Small Cap stock.
Last quarter Alpha Tau Medical Ltd. - reported $0 in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-113,600 and missed earnings estimates by -$.14.
In the last 3 years, DRTS traded as high as $14.11 and as low as $1.75.
The top ETF exchange traded funds that DRTS belongs to (by Net Assets): IZRL, EHLS, AVSD.
DRTS has outperformed the market in the last year with a return of +313.9%, while the SPY ETF gained +18.5%. In the last 3 month period, DRTS beat the market returning +54.5%, while SPY returned +4.5%. However, in the most recent 2 weeks DRTS has underperformed the stock market by returning -1.7%, while SPY returned -1.4%.
DRTS support price is $11.87 and resistance is $13.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRTS shares will trade within this expected range on the day.